Tag: Arovella Therapeutics
Arovella’s ALA-101 inches toward clinic following key manufacturing achievement
Arovella Therapeutics Ltd, the biotechnology company specialising in iNKT cell therapy, announced that the Good Manufacturing Practice (GMP)-grade lentiviral vector for its lead product, ALA-101, has completed successful manufacturing and quality release testing.
Featured Article
Forecasting the future: GridBeyond’s new tool supports smarter energy planning
As Australia’s energy landscape grows more dynamic, businesses operating in the National Electricity Market (NEM) face increasing challenges – from rising costs and evolving regulations to the growing presence of decentralised and renewable energy sources.
